Illumina Beheer

Beheer criteriumcontroles 2/4

De CEO Illumina is Jacob Thaysen, benoemd in Sep2023, heeft een ambtstermijn van 1.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.69M, bestaande uit 5.3% salaris en 94.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde € 1.12M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 6.3 jaar.

Belangrijke informatie

Jacob Thaysen

Algemeen directeur

US$4.7m

Totale compensatie

Percentage CEO-salaris	5.3%
Dienstverband CEO	1.2yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jacob Thaysen's beloning veranderd ten opzichte van Illumina's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 29 2024	n/a	n/a	-US$2b
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$5m	US$250k	-US$1b

Compensatie versus markt: De totale vergoeding ($USD 4.69M ) Jacob } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.81M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Jacob te vergelijken met de prestaties van het bedrijf.

CEO

Jacob Thaysen (49 yo)

1.2yrs

Tenure

US$4,691,233

Compensatie

Mr. Jacob Thaysen, Ph.D. serves as Chief Executive Officer at Illumina, Inc. since September 25, 2023 and serves as its Director since September 2023. Mr. Thaysen joined the Illumina, Inc. in September 202...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jacob Thaysen	CEO & Director	1.2yrs	US$4.69m	0.0056% € 1.1m
Carissa Rollins	Chief Information Officer	2.7yrs	US$2.93m	0.0018% € 354.6k
Charles Dadswell	Advisor	less than a year	US$4.10m	0.0044% € 886.6k
Stephanie Campos	President	no data	geen gegevens	geen gegevens
Kevin Pegels	Chief of Global Operations	3yrs	geen gegevens	0.010% € 2.1m
Scott Ericksen	VP & Chief Accounting Officer	2.1yrs	geen gegevens	0.0067% € 1.3m
Steven Barnard	Chief Technology Officer	1.3yrs	geen gegevens	0.017% € 3.4m
Sallilyn Schwartz	Vice President of Investor Relations	3.8yrs	geen gegevens	geen gegevens
Scott Davies	Interim General Counsel & Secretary	less than a year	geen gegevens	0.0084% € 1.7m
Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	less than a year	geen gegevens	0.0044% € 880.6k
Pat Leckman	Senior VP & Chief People Officer	less than a year	geen gegevens	0.0099% € 2.0m
Everett Cunningham	Chief Commercial Officer	less than a year	geen gegevens	0.0029% € 583.8k

1.2yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ILU wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jacob Thaysen	CEO & Director	1.2yrs	US$4.69m	0.0056% € 1.1m
Caroline Dorsa	Independent Director	7.8yrs	US$408.88k	0.0062% € 1.2m
Susan Siegel	Independent Director	5.8yrs	US$398.58k	0.0050% € 1.0m
Stephen MacMillan	Independent Chairman of the Board	1.4yrs	US$388.22k	0.00095% € 189.3k
Philip Schiller	Independent Director	8.3yrs	US$395.10k	0.0086% € 1.7m
Robert Epstein	Independent Director	12yrs	US$405.10k	0.0099% € 2.0m
Gary Guthart	Independent Director	6.9yrs	US$404.29k	0.0063% € 1.3m
Scott Ullem	Independent Director	1.4yrs	US$345.03k	0.0013% € 259.0k
Frances Arnold	Independent Director	8.8yrs	US$400.10k	0.0092% € 1.8m
Leslie Biesecker	Member of Ethics Advisory Board	no data	geen gegevens	geen gegevens
Scott Gottlieb	Independent Director	4.8yrs	US$391.37k	0.0035% € 699.3k
Clement Adebamowo	Member of Ethics Advisory Board	no data	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ILU wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Illumina Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Illumina, Inc. Announces Executive Changes

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Announces CEO Changes

Recent updates

Illumina, Inc. Announces Expansion of TruSight Oncology Portfolio

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting

Illumina, Inc. Introduces the MiSeq i100 Series

Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Second quarter 2024 earnings released: US$12.50 loss per share (vs US$1.48 loss in 2Q 2023)

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Now 21% undervalued

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Illumina, Inc. Appoints Anna Richo to its Board of Directors

First quarter 2024 earnings released: US$0.79 loss per share (vs US$0.019 profit in 1Q 2023)

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 24% undervalued after recent price drop

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: US$7.35 loss per share (vs US$28.05 loss in FY 2022)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 21% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

New minor risk - Share price stability

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Third quarter 2023 earnings released: US$4.77 loss per share (vs US$24.31 loss in 3Q 2022)

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.48 loss per share (vs US$3.41 loss in 2Q 2022)

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Illumina, Inc. Announces CEO Changes

Illumina, Inc. Announces Board Changes

Illumina Unveils AI Software to Predict Disease-Causing Genetic Mutations in Patients

Chief Commercial Officer recently sold €966k worth of stock

Illumina, Inc. Announces Board Changes

First quarter 2023 earnings released: EPS: US$0.019 (vs US$0.55 in 1Q 2022)

Full year 2022 earnings released: US$28.05 loss per share (vs US$5.08 profit in FY 2021)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Illumina Appoints Joydeep Goswami as Chief Financial Officer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$24.31 loss per share (vs US$2.09 profit in 3Q 2021)

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022

Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Illumina, Inc. Announces Resignation of Jose Torres as Chief Accounting Officer, Effective as of October 14, 2022

Illumina Intends to Appeal EC's Decision in Grail Deal

Second quarter 2022 earnings released: US$3.41 loss per share (vs US$1.27 profit in 2Q 2021)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022